RNAi沉默4-1BB基因表达抗大鼠肝移植急性排斥反应的实验研究
|
摘要
目的
⑴构建针对大鼠T淋巴细胞4-1BB基因编码区的小发夹RNA(shRNA)表达质粒和慢病毒载体系统,观察RNA(RNAi)对大鼠T淋巴细胞共刺激分子4-1BB基因表达和功能的影响。
⑵探讨阻断T淋巴细胞4-1BB/4-1BBL共刺激通路在大鼠肝移植急性排斥反应中的作用。
方法
⑴根据RNAi作用原理,设计、合成4条T淋巴细胞4-1BB基因的shRNA(shRNA441、shRNA540、shRNA621、shRNA758),插入质粒pGPU6,构建4个编码目的shRNA的表达质粒(p441、p540、p621、p758),酶切及测序鉴定。设对照组,利用电穿孔法在体外将目的基因片段导入BN大鼠T淋巴细胞,48小时后,半定量逆转录-聚合酶链反应(RT-PCR)和流式细胞术(FCM)检测其对T细胞4-1BB基因表达的抑制作用,并筛选、确定最佳效果的干扰质粒。
⑵利用筛选出的质粒,PCR扩增其中的U6+shRNA序列,克隆至慢病毒转移质粒pcDNA-CMV-Lentivector并经酶切和测序鉴定,与包装质粒以脂质体介导共转染293T细胞,产生shRNA重组慢病毒。病毒颗粒感染BN大鼠T淋巴细胞6～8 h后,与经丝裂霉素处理的Lewis大鼠淋巴细胞作单项混合淋巴细胞反应,设对照组和干扰组。RT-PCR、FCM、Western bloting方法检测4-1BB表达,MTT、3H-TdR检测干扰后T细胞的增殖能力,FCM测定凋亡细胞数,ELISA法检测细胞因子IL-2、IL-10、IFN-γ水平。
⑶“二袖套法”行Lewis鼠到Brown Norway(BN)鼠原位肝移植24例,大鼠随机分成实验对照组、阴性对照组和干涉实验组,每组8对。三组的受体鼠分别在移植前12 h经阴茎背静脉注射1 ml生理盐水、空病毒和重组病毒液。于术后第5天每组处死BN鼠3只,取脾脏,RT-PCR、FCM检测在体T细胞4-1BB表达;取下腔静脉血检测细胞因子和生化指标;取肝组织观察病理变化;剩余大鼠观察术后生存情况。
结果
⑴经酶切反应及测序证实构建成功重组干扰质粒p441、p540、p621和p758,转染T细胞后,4-1BB相对表达量分别为(33.4±2.3)%、(53.0±2.3)%、(62.1±3.1)%、(40.9±1.5)%,对照组4-1BB相对表达量为(67.2±1.5)%。其中p441沉默效果最佳(p<0.01)。
⑵经酶切反应及测序证实,重组慢病毒转移质粒pLVs441序列正确,包装产生病毒液(LVs441)滴度在5×106 TU/ml,浓缩后约3×108 TU/ml。LVs441感染T细胞效率约90%,干涉组4-1BB表达量显著下降(p<0.01);T细胞凋亡较明显(p<0.05);T细胞增殖能力、IL-2,IFN-γ水平低于实验对照组。
⑶干涉组BN鼠脾淋巴细胞4-1BB表达量低于对照组(p<0.05);两组IL-10、T-BIL水平无明显差别,但干涉组IL-2、IFN-γ和ALT、AST、LDH水平均低于对照组(p<0.05);对照组和干涉组大鼠肝组织急性排斥Banff评分分别为7.11±0.78、5.89±1.05(p=0.0384)、平均生存时间分别为10.4±1.95天和29±14.78天(p<0.05)。
结论
⑴siRNA可特异性抑制大鼠T淋巴细胞共刺激分子4-1BB基因转录和表达,诱发T细胞凋亡,抑制大鼠T细胞的增殖能力,降低IL-2,IFN-γ等细胞因子的分泌水平。
⑵RNAi阻断T细胞4-1BB/4-1BBL共刺激通路,可抑制肝移植大鼠急性排斥反应,延长受体存活时间。
⑶电穿孔技术是质粒载体转染原代T淋巴细胞的一种有效方法。
⑷慢病毒载体系统是携带siRNA进入T细胞的理想载体。
Objectives
⑴To construct 4-1BB specific small hairpin RNA(shRNA) expression plasmids as well as lentiviral vector,and observe the expression of 4-1BB costimulatory molecule on rat lymphocytes inhibited by small interfering RNA(siRNA).
⑵To investigate the role of blockade of 4-1BB/4-1BBL costimulatory pathway with RNA interference(RNAi) in acute rejection of rat orthotopic liver transplantation.
Methods
⑴According to the mechanism of RNAi, 4 expression sequences of shRNA target to rat lymphocyte 4-1BB were designed(shRNA441、shRNA540、shRNA621、shRNA758), and inserted into expression vector pGPU6. The recombined plasmid vectors(p441、p540、p621、p758) were identified by restriction enzyme analysis and sequencing,then, transfected into rat lymphocytes with electroporation. The changes of 4-1BB mRNA level and gene expression were determined by semi-quantitative Reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry(FCM)at 48 h post transfection, meanwhile, one of the recombined plasmids was judged optimization for following experiments.
⑵The sequence of U6 + shRNA was obtained from the optimization recombined plasmid by PCR amplification, and cloned to lentivirus tansfer vector pcDNA-CMV- Lentivector. identified with restriction endonuclease digestion and sequencing, recombined tansfer vector pLVs/shRNA and other package plasmids were cotransfected to 293T cells with the help of lipofectamine 2000 to produce Lentivirus(LVs). Lymphocytes from BN rats as well as Lewis rats were respectively infected by LVs and pretreated by mitomycin C(MMC),then,the mixed lymphocyte reaction(MLR) were performed. RT-PCR, FCM and Western blot assay were employed to assess the expression of 4-1BB. Apoptosis was monitored by FCM also.The cell reproductive activity were detected by MTT and 3H-TdR.cytokine such as IL-2,IL-10 and IFN-γlevels were assayed by commercial ELISA kits.
⑶24 cases of orthotopic liver transplantation were performed in Lewis to BN rats by using“the two-cuff technique”,and all rats were divided into experimental contrast group, negative control group and interference group randomly. The BN rats of 3 groups were injected saline, empty LVs and recombinant LVs via the dorsal penis vein respectively before operation. On the 5th day after transplantation, 3 rats in each group were killed. The lymphocytes were obtained from spleen to detect the 4-1BB expression by RT-PCR and FCM. blood samples were drawn from inferior vena cava for biochemistry tests and cytokine assay. liver lobes were excised to study the pathological changes. Postoperative survival time of the rats in each group was recorded also.
Results
⑴The interferential plasmid p441、p540、p621 and p758 were successfully constructed identified with restriction endonuclease digestion and sequencing. Relative expression of 4-1BB on activated T lymphocytes subjected to those plasmid were (33.4±2.3)%,(53.0±2.3)%,(62.1±3.1)% and (40.9±1.5)% respectively,while (67.2±1.5)% in control group. Silencing effect of p441 was the best.
⑵Recombined lentivirus tansfervector LVs441 was also identified by restriction enzyme analysis and sequencing. The lentivirus was produced successfully by 293T cells with titer of 5×106 TU/ml,even 3×108 TU/ml if concentrating was carried out.90% T cells could be infected by LVs441, expression of 4-1BB was decreased(p<0.01), and the apoptosis T cell numbers increased in interference group, T cells reproductive activity and cytokine levels in interference group were lower than those in control group.
⑶In vivo,the expression of 4-1BB in interference group was lower than those in control group,and levels of IL-2,IFN-γ,ALT,AST,LDH were decreased too.Banff scores calculated by the degree of acute cellular rejection in two groups were 7.11±0.78 and 5.89±1.05(p=0.0384),while the mean survival time were (11.00±4.28) and (12.75±5.57) days respectively(p<0.05).
conclusions
⑴siRNA could decrease the expression of 4-1BB mRNA and protein, induce T cells to apoptosis. furthermore, the proliferation of rat T cells and the levels of cytokine production were inhibited.
⑵RNAi could inhibit T cell costimulatory pathway, prevent acute rejection,and prolong survival.
⑶Electroporation technique was an effective method for transfecting plasmid to some difficult-transfection cells,such as T lymphocytes.
⑷Lentivirus was an appropriate and efficient vector to deliver siRNA into T lymphocytes.
⑴构建针对大鼠T淋巴细胞4-1BB基因编码区的小发夹RNA(shRNA)表达质粒和慢病毒载体系统,观察RNA(RNAi)对大鼠T淋巴细胞共刺激分子4-1BB基因表达和功能的影响。
⑵探讨阻断T淋巴细胞4-1BB/4-1BBL共刺激通路在大鼠肝移植急性排斥反应中的作用。
方法
⑴根据RNAi作用原理,设计、合成4条T淋巴细胞4-1BB基因的shRNA(shRNA441、shRNA540、shRNA621、shRNA758),插入质粒pGPU6,构建4个编码目的shRNA的表达质粒(p441、p540、p621、p758),酶切及测序鉴定。设对照组,利用电穿孔法在体外将目的基因片段导入BN大鼠T淋巴细胞,48小时后,半定量逆转录-聚合酶链反应(RT-PCR)和流式细胞术(FCM)检测其对T细胞4-1BB基因表达的抑制作用,并筛选、确定最佳效果的干扰质粒。
⑵利用筛选出的质粒,PCR扩增其中的U6+shRNA序列,克隆至慢病毒转移质粒pcDNA-CMV-Lentivector并经酶切和测序鉴定,与包装质粒以脂质体介导共转染293T细胞,产生shRNA重组慢病毒。病毒颗粒感染BN大鼠T淋巴细胞6～8 h后,与经丝裂霉素处理的Lewis大鼠淋巴细胞作单项混合淋巴细胞反应,设对照组和干扰组。RT-PCR、FCM、Western bloting方法检测4-1BB表达,MTT、3H-TdR检测干扰后T细胞的增殖能力,FCM测定凋亡细胞数,ELISA法检测细胞因子IL-2、IL-10、IFN-γ水平。
⑶“二袖套法”行Lewis鼠到Brown Norway(BN)鼠原位肝移植24例,大鼠随机分成实验对照组、阴性对照组和干涉实验组,每组8对。三组的受体鼠分别在移植前12 h经阴茎背静脉注射1 ml生理盐水、空病毒和重组病毒液。于术后第5天每组处死BN鼠3只,取脾脏,RT-PCR、FCM检测在体T细胞4-1BB表达;取下腔静脉血检测细胞因子和生化指标;取肝组织观察病理变化;剩余大鼠观察术后生存情况。
结果
⑴经酶切反应及测序证实构建成功重组干扰质粒p441、p540、p621和p758,转染T细胞后,4-1BB相对表达量分别为(33.4±2.3)%、(53.0±2.3)%、(62.1±3.1)%、(40.9±1.5)%,对照组4-1BB相对表达量为(67.2±1.5)%。其中p441沉默效果最佳(p<0.01)。
⑵经酶切反应及测序证实,重组慢病毒转移质粒pLVs441序列正确,包装产生病毒液(LVs441)滴度在5×106 TU/ml,浓缩后约3×108 TU/ml。LVs441感染T细胞效率约90%,干涉组4-1BB表达量显著下降(p<0.01);T细胞凋亡较明显(p<0.05);T细胞增殖能力、IL-2,IFN-γ水平低于实验对照组。
⑶干涉组BN鼠脾淋巴细胞4-1BB表达量低于对照组(p<0.05);两组IL-10、T-BIL水平无明显差别,但干涉组IL-2、IFN-γ和ALT、AST、LDH水平均低于对照组(p<0.05);对照组和干涉组大鼠肝组织急性排斥Banff评分分别为7.11±0.78、5.89±1.05(p=0.0384)、平均生存时间分别为10.4±1.95天和29±14.78天(p<0.05)。
结论
⑴siRNA可特异性抑制大鼠T淋巴细胞共刺激分子4-1BB基因转录和表达,诱发T细胞凋亡,抑制大鼠T细胞的增殖能力,降低IL-2,IFN-γ等细胞因子的分泌水平。
⑵RNAi阻断T细胞4-1BB/4-1BBL共刺激通路,可抑制肝移植大鼠急性排斥反应,延长受体存活时间。
⑶电穿孔技术是质粒载体转染原代T淋巴细胞的一种有效方法。
⑷慢病毒载体系统是携带siRNA进入T细胞的理想载体。
Objectives
⑴To construct 4-1BB specific small hairpin RNA(shRNA) expression plasmids as well as lentiviral vector,and observe the expression of 4-1BB costimulatory molecule on rat lymphocytes inhibited by small interfering RNA(siRNA).
⑵To investigate the role of blockade of 4-1BB/4-1BBL costimulatory pathway with RNA interference(RNAi) in acute rejection of rat orthotopic liver transplantation.
Methods
⑴According to the mechanism of RNAi, 4 expression sequences of shRNA target to rat lymphocyte 4-1BB were designed(shRNA441、shRNA540、shRNA621、shRNA758), and inserted into expression vector pGPU6. The recombined plasmid vectors(p441、p540、p621、p758) were identified by restriction enzyme analysis and sequencing,then, transfected into rat lymphocytes with electroporation. The changes of 4-1BB mRNA level and gene expression were determined by semi-quantitative Reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry(FCM)at 48 h post transfection, meanwhile, one of the recombined plasmids was judged optimization for following experiments.
⑵The sequence of U6 + shRNA was obtained from the optimization recombined plasmid by PCR amplification, and cloned to lentivirus tansfer vector pcDNA-CMV- Lentivector. identified with restriction endonuclease digestion and sequencing, recombined tansfer vector pLVs/shRNA and other package plasmids were cotransfected to 293T cells with the help of lipofectamine 2000 to produce Lentivirus(LVs). Lymphocytes from BN rats as well as Lewis rats were respectively infected by LVs and pretreated by mitomycin C(MMC),then,the mixed lymphocyte reaction(MLR) were performed. RT-PCR, FCM and Western blot assay were employed to assess the expression of 4-1BB. Apoptosis was monitored by FCM also.The cell reproductive activity were detected by MTT and 3H-TdR.cytokine such as IL-2,IL-10 and IFN-γlevels were assayed by commercial ELISA kits.
⑶24 cases of orthotopic liver transplantation were performed in Lewis to BN rats by using“the two-cuff technique”,and all rats were divided into experimental contrast group, negative control group and interference group randomly. The BN rats of 3 groups were injected saline, empty LVs and recombinant LVs via the dorsal penis vein respectively before operation. On the 5th day after transplantation, 3 rats in each group were killed. The lymphocytes were obtained from spleen to detect the 4-1BB expression by RT-PCR and FCM. blood samples were drawn from inferior vena cava for biochemistry tests and cytokine assay. liver lobes were excised to study the pathological changes. Postoperative survival time of the rats in each group was recorded also.
Results
⑴The interferential plasmid p441、p540、p621 and p758 were successfully constructed identified with restriction endonuclease digestion and sequencing. Relative expression of 4-1BB on activated T lymphocytes subjected to those plasmid were (33.4±2.3)%,(53.0±2.3)%,(62.1±3.1)% and (40.9±1.5)% respectively,while (67.2±1.5)% in control group. Silencing effect of p441 was the best.
⑵Recombined lentivirus tansfervector LVs441 was also identified by restriction enzyme analysis and sequencing. The lentivirus was produced successfully by 293T cells with titer of 5×106 TU/ml,even 3×108 TU/ml if concentrating was carried out.90% T cells could be infected by LVs441, expression of 4-1BB was decreased(p<0.01), and the apoptosis T cell numbers increased in interference group, T cells reproductive activity and cytokine levels in interference group were lower than those in control group.
⑶In vivo,the expression of 4-1BB in interference group was lower than those in control group,and levels of IL-2,IFN-γ,ALT,AST,LDH were decreased too.Banff scores calculated by the degree of acute cellular rejection in two groups were 7.11±0.78 and 5.89±1.05(p=0.0384),while the mean survival time were (11.00±4.28) and (12.75±5.57) days respectively(p<0.05).
conclusions
⑴siRNA could decrease the expression of 4-1BB mRNA and protein, induce T cells to apoptosis. furthermore, the proliferation of rat T cells and the levels of cytokine production were inhibited.
⑵RNAi could inhibit T cell costimulatory pathway, prevent acute rejection,and prolong survival.
⑶Electroporation technique was an effective method for transfecting plasmid to some difficult-transfection cells,such as T lymphocytes.
⑷Lentivirus was an appropriate and efficient vector to deliver siRNA into T lymphocytes.
引文
[1] Dawwas MF,Gimson AE,Lewsey JD,et al.Survival after liver transplantation in the United Kingdom and Ireland compared with the United States.Gut,2007,56(11):1606-1613.
[2] Perrella O,Sbreglia C,Arenga G,et al. Acute rejection after liver transplantation: Is there a specific immunological pattern?Transplant Proc. 2006;38(10):3594-3596.
[3] Michel F,Attal Bonnefoy G,Mangino G,et al.CD28 as a molecular amplifier extending TCR ligation and signaling capabilities.Immunity,2001,15(6):935-945.
[4] Polte T,Foell J,Werner C,et a1. CD137-mediated immunotherapy for allergic asthma.J Clin Invest,2006,116(4):1025-36.
[5] Vidric M,Suh WK,Dianzani U,et a1.Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice.J Immunol,2005,175(11):7288-7296.
[6] Dillin A. The specifics of small interfering RNA specificity. PNAS, 2003,100(11):6289-6291;
[7] Sledz CA and Williams BRG. RNA interference in biology and disease. Blood. 2005;106(3):787-794.
[8] Culien B R.Does RNA interference have a future as a treatment for HIV-l induced diseasel.AIDS Rev,2O05,7(1):22-25.
[9] Mccafikey A P,Nakai H,Pandey et a1.Inhibition hepatitis B virus in mice by RNA interference.Nat Biotechnol,20O3,21(6):639-644.
[1] Kim J,Choi WS,Ls S,et al. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells.Blood. 2005,105(5):2206-2213.
[2] Kocak E, Lute K, Chang X, et al.Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity. Cancer Research,2006,66: 7276-7284.
[3] Wehler T C, Nonn M, Brandt B,et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood, 2007, 109(1):365-373.
[4] Fire A, Xu S, Montgomery MK. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature,1998; 391(6669): 806-811.
[5] Geanacopoulos M. An introduction to RNA-mediated gene silencing. Sci Prog. 2005;88(Pt1): 49-69.
[6] Elbashir SM, Harborth J, Weber K, et al. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 2002; 26(2): 199-213.
[7] Lovett-Racke AE, Cravens PD, Gocke AR, et al. Therapeutic potential of small interfering RNA for central nervous system diseases. Arch Neurol. 2005; 62(12):1810-1813.
[8] Meins F, Si-Ammour A, Blevins T. RNA silencing systems and their relevance to plant development. Annu Rev Cell Dev Biol,2005; 21: 297-318.
[9] Brummelkamp TR, Bernards R, Agami R, et al. A system for stable expression of short interfering RNAs in mammalian cells. Science,2002; 296(5567): 550-553.
[10] Gong Y, Jennifer AT, Bingliang F, et al. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer.Oncogene, 2003; 22(36): 5694–5701.
[11] Hu WY,Bushman FD,Siva. RNA interference against retroviruses. VirusRes,2004;102(1):59-64.
[12] Christensen HS,Daher A,Soye KJ,Frankel,et al.Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production.J Virol. 2007;81(10):5121-5131.
[13] Kim J,Choi SP,La S,et al.Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses.Exp Mol Med. 2003;35(6):509-517.
[14] Al-Shamkhani A.CD137: costimulator turns suppressor?Immunology. 2004 ,113(1):23-25.
[15] Sun Y,Chen JH,Fu Y.Immunotherapy with agonistic anti-CD137: two sides of a coin.Cell Mol Immunol. 2004 ;1(1):31-36.
[16] Nam KO,Kang WJ,Kwon BS,et al. The therapeutic potential of 4-1BB (CD137) in cancer.Curr Cancer Drug Targets. 2005;5(5):357-363.
[17] Miyagishi M,Taira K.U6 promoter-driven siRNAs with four uridine 3’- verhangs efficiently suppress targeted gene expression in mammalian cells . Nat Biotechnol.2002,20(5):497-500.
[18] Ohmori T,Kashiwakura Y,Ishiwata A,et al. Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence.Arterioscler Thromb Vasc Biol. 2007,27(10):2266 -2272.
[19] Wakiyama M,Matsumoto T,Yokoyama. Drosophila U6 promoter-driven short hairpin RNAs effectively induce RNA interference in Schneider 2 cells.Biochem Biophys Res Commun. 2005 Jun 17;331(4):1163-1170.
[20] Boden D,Pusch O, Lee F,et al.Promoter choice affects the potency of HIV-1 specific RNA interference.Nucleic Acida Res,2003,3l(17):5033-5038.
[21] Eefting D,Grimbergen JM,de Vries MR,et al.Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA.Hum Gene Ther. 2007;18(9):861-869.
[22] McManus MT, Haines BB, Dillon CP, et al.Small Interfering RNA-Mediated GeneSilencing in T Lymphocytes. The Journal of Immunology, 2002, 169: 5754–5760.
[23] Lofblom J,Kronqvist N,Uhlen M,et al.Optimization of electroporation-mediated transformation: Staphylococcus carnosus as model organism.J Appl Microbiol. 2007;102(3):736-747.
[24] Bassett CL,Janisiewicz WJ. Electroporation and stable maintenance of plasmid DNAs in a biocontrol strain of Pseudomonas syringae.Biotechnol Lett. 2003;25(3):199-203.
[25] Tryfona T,Bustard MT. Enhancement of biomolecule transport by electroporation: a review of theory and practical application to transformation of Corynebacterium glutamicum.Biotechnol Bioeng. 2006;93(3):413-423.
[1] Scherr M,Morgan MA and Eder M.Gene Silencing mediated by small interfering RNAs in mammalian cells.Curr Med Chem,2003,10(3):245-256.
[2] Ginn SL,Fleming J,Rowe PB,et al.Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner.Hum Gene Ther. 2003;14(12):1127-1137.
[3] Logan AC,Haas DL,Kafri T,et al.Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration.J Virol. 2004;78(16):8421-8436.
[4] Sachdeva G,Dcosta J,Cho JE,et al.Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.J Med Virol. 2007;79(2):118-126.
[5] Semple-Rowland SL,Eccles KS and Humberstone EJ.Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters.Mol Vis. 2007;13:2001-2011.
[6] Philippe S,Sarkis C,Barkats M,et al.Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo.Proc Natl Acad Sci U S A. 2006;103(47):17684-17689.
[7] Bao L,Jaligam V,Zhang XY,et al. Stable transgene expression in tumors and metastases after transduction with lentiviral vectors based on human immunodeficiency virus type 1.Hum Gene Ther. 2004;15(5):445-456.
[8] Brummelkamp TR,Bemards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science ,2002,296:550～553.
[9] Amarzguioui M,Rossi JJ and Kim D.Approaches for chemically synthesized siRNA and vector-mediated RNAi.FEBS Lett. 2005;579(26):5974-5981.
[10] Hua J,Mutch DG and Herzog TJ.Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cellline.Gynecol Oncol. 2005;98(1):31-38.
[11] Aigner A.Nonviral in vivo delivery of therapeutic small interfering RNAs.Curr Opin Mol Ther. 2007;9(4):345-352.
[12] Kasahara H and Aoki H. Gene silencing using adenoviral RNAi vector in vascular smooth muscle cells and cardiomyocytes.Methods Mol Med. 2005;112:155-72.
[13] Storvold GL,Gjernes E,Askautrud HA,et al.A retroviral vector for siRNA expression in mammalian cells.Mol Biotechnol. 2007;35(3):275-282.
[14] Matta H,Hozayev B,Tomar R,et al.Use of lentiviral vectors for delivery of small interfering RNA.Cancer Biol Ther. 2003;2(2):206-210.
[15] Gropp M and Reubinoff BE. Lentiviral-RNA-interference system mediating homogenous and monitored level of gene silencing in human embryonic stem cells.Cloning Stem Cells. 2007;9(3):339-45.
[16] Liu YP,Haasnoot J and Berkhout B.Design of extended short hairpin RNAs for HIV-1 inhibition.Nucleic Acids Res. 2007;35(17):5683-5693.
[17] Kim YJ,Ahn J,Jeung SY,et al. Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model.Virus Genes. 2008;36(1):141-146.
[18] Lee SW,Park Y,Song A,et al.Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.J Immunol. 2006;177(7):4464-4472.
[19] Wehler TC,Nonn M,Brandt B,et al.Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.Blood. 2007;109(1):365-373.
[20] Zhang H,Snyder KM,Suhoski MM,et al.4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.J Immunol. 2007;179(7):4910-4918.
[21] Waller EC,Mckinney N,Hicks R,et al. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells.Blood. 2007;110(13):4360-4366.
[22] Sarai M,Hartung D,Petrov A,et al. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging.J Am Coll Cardiol. 2007;50(24):2305-2312.
[23] Wiegard C,Wolint P,Frenzel C,et al. Defective T helper response of hepatocyte-stimulated CD4 T cells impairs antiviral CD8 response and viral clearance.Gastroenterology. 2007;133(6):2010-2018.
[1] Kashfi A, Mehrabi A, Pahlavan PS,et al.A review of various techniques of orthotopic liver transplantation in the rat[J].Transplant Proc, 2005; 37(1): 185-188.
[2] Kamada N,Calne RY.A surgical experience with five hundred thirty liver transplantation in the rat[J].Surgery,1983, 93(1 Pt 1): 64-69.
[3]秦磊,高广勇,余斌,等.改良二袖套法大鼠原位肝脏移植150例报告[J].苏州大学学报(医学版),2005,25(1):77-80.
[4]马毅,何晓顺,陈规划.大鼠原位肝移植模型的手术技巧及并发症的预防[J].中华显微外科杂志,2003,26(1):45-47.
[5]李军,窦科峰,赵青川,等.两套袖法大鼠原位肝移植模型的建立及改进[J].第四军医大学学报,2006,27(9):835-837.
[6] Holzen JP, Palmes D, Langer M,et al.Microsurgical training curriculum for learning kidney and liver transplantation in the rat[J]. Microsurgery,2005, 25(8): 614-623.
[7]刘金彪,郑树国,张玉君,等.提高大鼠原位肝移植手术质量的技巧和注意事项[J].中华器官移植杂志,2005, 26 (8):500-502.
[1] Cho HR,Kwon B,Yagita H,et al.Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.Transpl Int,2004;17(7):351-361.
[2] Detry O,De Roover A,Coimbra C,et al. Recent advances in liver surgery and transplantation. Rev Med Liege. 2007;62(5-6):310-316.
[3] Sugawara Y and Makuuchi M.Liver transplantation for hepatitis B-related cirrhosis: recent advances.J Hepatobiliary Pancreat Surg. 2006;13(5):378-381.
[4] Reding R. Contribution to the study of mechanisms of rejection and tolerance in organ transplantation: minimizing immunosuppression as a strategy for graft tolerance in pediatric liver transplantation.Bull Mem Acad R Med Belg. 2005;160(5-6):265-269.
[5] Perrella O,Sbreglia C,Arenga G,et al. Acute rejection after liver transplantation: Is there a specific immunological pattern?Transplant Proc. 2006;38(10):3594-3596.
[6] Yilmaz F,Aydin U,Nart D,et al. The incidence and management of acute and chronic rejection after living donor liver transplantation.Transplant Proc. 2006;38(5):1435-1437.
[7] Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation, 2004, 77(12): 1815-1820.
[8] Gibelli NE, Pinho-Apezzato ML, et al. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: comparative study. Transplant Proc, 2004, 36(4): 956-957
[9] Suciu-Foca N, Cortesini R. Reviewing the mechanism of peripheral tolerance in clinical transplantation. Contrib Nephrol, 2005, 146(1): 132-142.
[10] Neujahr D, Turka LA. Lymphocyte depletion as a barrier to immunological tolerance[J]. Contrib Nephrol, 2005, 146(1): 65-72.
[11] Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest, 2004, 114(10): 1398-1403.
[12] Kvist M,Lemplesis V,Kanje M,et al. Immunomodulation by costimulation blockade inhibits rejection of nerve allografts.J Peripher Nerv Syst. 2007;12(2):83-90.
[13] Malm H,Pahlman C,Veress B,et al. Combined costimulation blockade prevents rejection of allogeneic islets in mice.Scand J Immunol. 2006;64(4):398-403.
[14] Hosiawa KA,Wang H,DeVries ME,et al. CD80/CD86 costimulation regulates acute vascular rejection.J Immunol. 2005;175(9):6197-6204.
[15] Guillonneau C,Seveno C,Dugast AS,et al. Anti-CD28 antibodies modify regulatorymechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients.J Immunol. 2007;179(12):8164-8171.
[16] Haspot F,Seveno C,Dugast AS,et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells.Am J Transplant. 2005;5(10):2339-2348.
[17] Fan K,Wang H,Wei H,et al. Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance. Transplantation. 2007;84(6):746-754.
[18] McNamara JO,Kolonias D,Pastor F,et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.J Clin Invest. 2008;118(1):376-386.
[19] Elpek KG,Yolcu ES,Franke DD,et al. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.J Immunol. 2007;179(11):7295-7304.
[20] Kroczek R and Hamelmann E. T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies.J Allergy Clin Immunol. 2005;116(4):906-909.
[21] Cao H,Liu H and Wu ZY.Effects of combined immune therapy on survival and Th1/Th2 cytokine balance in rat orthotopic liver transplantation.Chin Med J (Engl). 2007;120(20):1809-1812
[22] Wehler TC,Nonn M,Brandt B,et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood,2007;109(1):365-373.
[23] Rautajoki K,Nyman TA,Lahesmaa R. Proteome characterization of human T helper 1 and 2 cells.Proteomics,2004,4(1):84-92.
[24] Hase T,Chargui J,Inori F,et a1.Human interleukin-10 transduced fetal liver stem cells prolong survival of mouse skin and heart allografts.Transplant Proc,2005,37(1):287-288.
[1] Welch CS. A note on transplantation of the whole liver in dogs.Transplant Bull,1955.2:54.
[2] Cnon JA.Brief report.Transplant Bull,1956.3:7.
[3] Moore FD, Smith LL. Burnap TK, et a1. One-stage homotransplantation of the liver following total hepatectomy in dogs.Transplant Bull,1959, 6(1):103-11O.
[4] Starzl TE,Marchioro TL,VonKaulla KN。et a1. Homotransplantation of the liver in humans.Surg Gynecol Obstet,1963,117:659-676.
[5] Peter S,Heeger.T-Cell alloreeognition transplant rejection:a summary and update.Am J Transplant,2003,3(5):525-533.
[6] Peggs KS,Allison JP.Co-stimulatory pathways in lymphocyte regulation:the imrnuno--globulin superfamily.Br j Haematol,2005,130(6):809-824.
[7] Cho HR,Kwon B,Yagita H,et al.Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.Transpl Int,2004;17(7):351- 361.
[8] Rautajoki K,Nyman TA,Lahesmaa R. Proteome characterization of human T helper 1 and 2 cells.Proteomics,2004,4(1):84-92.
[9] Hase T,Chargui J,Inori F,et a1.Human interleukin-10 transduced fetal liver stem cells prolong survival of mouse skin and heart allografts.Transplant Proc,2005,37(1):287-288.
[10] Aharoni R,Teitelbaum D,Arnon R,et a1.Copolymer 1 inhibits manifestations of graft rejection. Transplantation,2001,72(2):598-605.
[11] Bittmann I,Muller C,Behr J,et a1.Fas/FasL and perforin/granzyme pathway in acute rejection and diffuse alveolar damage after allogeneic lung transplantation - a human biopsy study.Virchows Arch,2004,445(4):375-381.
[12] Ji J,Yu YY,Chen H,et a1.Perforin and granzyme B expression in liver allograft rejection. Zhonghua Gan zang Bing Za Zhi,2004,12(6):325-327.
[13] Thomson Aw ,OConnell PJ,Steptoe RJ,et a1.Immunobiology of liver dendritic cells.Immunol Cell Biol,2002,80(1):65-73.
[14] Weiler-Normann C , Rehermann B.The liver as an Immunological organ . J Gastroenterol Hepatol,2004,19(7):279-283.
[15] Haase C,M Ichdsen BK,Jorgensen TN.CD40 is necessary for activation of naive T cells by a dendritic cell line in vivo but not in vitro.Scand J Immunol,2004,59(3):237-245.
[16] Rentsch M,Puellmann K,Sirek S,et a1.Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat:effects on postischemic reperfusion injury , apoptotic cell death graft regeneration and surviva1.Transpl Int,2005,18(9):1079-1089.
[17] Bertolino P,McCaughan GW,Bowen DG.Role of primary intrahepatic T-cell activation in the liver tolerance effect.Immunol Cell Biol,2002,80(1):84-92.
[18] Fukushi J,Ono M,Morikawa W,et a1.The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13.Immunol,2000,165(5):2818-2823.
[19] Barnes EJ,Abdel-Rehim MM,Goulis Y,et a1.Applications and limitations of blood eosinophilia for the diagnosis of acute cellular rejection in liver transplantation. Am J Transplant,2003,3(4):432-438.
[20] Bishop GA,Sun J,Sheil AG,et a1.High-dose/activation-associated tolerance:a mechanism for allograft tolerance.Transplantation,1997,64:l377-l382.
[21] Yang ZF Ho DW,Chu AC,et a1.Linking inflammation to acut rejection in smal1-for-size liver allografts:the potential role of early macrophage activation.Am J Transplant,2004,4(2):196-209.
[22] Kasahara M,Uryuhara K,Kaihara S,et a1.Monosegmental living donor liver transplantation.Transplant Proc,2003,35(4):1425-1426.
[23] Kasahara M,Kaihara S,Oike F,et a1.Living-donor liver transplantation with monosegments.Transplantation,2003,76(4):694-696.
[24] Sacher T,Knolle P,Nichterlein T,et a1.CpG-ODN-induced inflammarion is suficient to cause T-cell-mediated autoaggression against hepatocytes.Eur J Immunol,2002,32(12):3628-3637.
[25] Kreisel D,Krupnick AS,Gelman AE,et a1.Non-hematopoietic allograft cells directly activate CD8+T cells and trigger acute rejection:all alterative mechanism of allorecognition.Nat Med.2002,8(3):233-239.
[26] Martelius T,Salaspuro V,Salmi M,et a1.Blockade of vascular adhesion protein-l inhibits lymphocyte infiltration in rat liver allograft rejection.Am J Pathol,2004,l65(6):l993-2001.
[27] Crispe IN.Hepatic T cells and liver tolerance.Nat Rev Immunol,2003,3(1):5l-62.
[28] Tesar BM,Zhang J,Li Q,et a1.Thl immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88,a toll-like receptor signal adaptor protein.Am J Transplant,2004,4(9):l429-1439.
[29] Apte UM,McRee R , Ramaiah SK . Hepatocyte proliferation is the possible mechanism for the transient decrease in liver injury during steatosis stage of alcoholic liver disease.Toxicol Pathol,2004,32(5):567-576.
[30] Matzinger P.Friendly and dangerous signals:is the tissue in control? Nat Immunol,2007,8(1):11-13.
[31] Fabrega E,Castro B,Crespo J,et a1.Different time course of circulating adhension molecules and hyaluran during hepatic allograft rejection. Transplantation,2000,69(4):569-573.
[32] Ala A,Dhillon AP,Hodgson HJ.Role of cell adhesion molecules in leukocyte recruitment in the liver and gut.Int J Exp Pathol,2003,84(1):1-56.
[33] Hussain AM,Zhang QX,Murray AG.Endothelial cell calpain activity facilitates lymphocyte diapedesis.Am J Transplant,2005,5(11):2640-2648.
[34] Limmer A , Knolle PA.Liver sinusoidal endothelial cells : a new type of organ-resident antigen-presenting cel1. Arch Immunol Ther Exp(Warsz),2001,49(1):7-11.
[35] Winn RK,Harlan JM.The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost,2005,3(2):1815-1824.
[36] Nakanuma Y,Tsuneyama K,Harada K.Pathology and pathogenesis of intrahepaticbile duct loss.J Hepatobiliary Pancreat Surg,2001,8(4):303-315.
[37] Taylor AL,Gibbs P,Bradley JA.Acute Graft versus host disease following liver transplantation:the enemy within.Am J Transpl,2004,4(4):466-474.
[38] Taylor AL,Sudhindran S,Key T ,et a1. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft versus-host- disease after liver transplantation.Transplantation,2004,77(3):441-446.
[39] Mandelbrot DA ,Sayegh MH.Role of novel T-cell costimulatory pathways in transplantation. Curr Opin Organ Transplantation,2003,8:25-33.
[40] Sudhindran S, Taylor A , Delrivierea L,et a1.Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection.Am J Transpl,2003,3(8):1024-1029.
[41] Huang YM ,Cramer DE ,Ray MB,et a1.The role ofαβ-T andγδ-T cells in allogeneic donor marrow on engraftment , chimerism , and graft-versus-host disease.TranspIantation,2001,72(12):1907-1914.
[42] COSIMI AB , SACHS DH . Mixed chimerism and transplantation tolerance.Transplantation,2004,77(6):943-946.
[43] TRIULZI DJ, NALESNIK MA. Microchimerism ,GVHD,and tolerance in solid organ transplantation.Transfusion,2001,41(3):419-424.
[44] MoNACO AP , MoRRIS PJ . Clinical tolerance : the end of the beginning.Transplantation,2004,77(6):921-925.
[45] SCHLITT HJ,RADDATZ G,STElNHOFF G,et a1.Passenger lymphocytes in human liver allografts and their potential role after transplantation.Transplantation,1993,56(4):95l-955.
[46] POLLACK MS,SPEEG KV,CAllANDER NS,et a1.Severe,late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis.Human Immunology,2005,66(1):28-31.
[47] Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids(3 day taper).Liver Transplant,200l,7(4):343-351.
[48] Barshes NR Goodpastor SE,Goss JA.Pharmacologic immunosuppression. Front Biosci,2004,9:4ll-42O.
[49] Moser MA.Options for induction immunosuppression in liver transplant recipients. Drugs,2002;62(7):995-1011.
[50] Vincenti F,Larsen C,Durrbach A.Costimulation blockade with belatacept in renal transplantation. N Engl Med,2005,353(8):770-781.
[51] changelian PS,Flanagan ME,Ball DJ,et al.Science,2003.302(5646):875-878.
[2] Perrella O,Sbreglia C,Arenga G,et al. Acute rejection after liver transplantation: Is there a specific immunological pattern?Transplant Proc. 2006;38(10):3594-3596.
[3] Michel F,Attal Bonnefoy G,Mangino G,et al.CD28 as a molecular amplifier extending TCR ligation and signaling capabilities.Immunity,2001,15(6):935-945.
[4] Polte T,Foell J,Werner C,et a1. CD137-mediated immunotherapy for allergic asthma.J Clin Invest,2006,116(4):1025-36.
[5] Vidric M,Suh WK,Dianzani U,et a1.Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice.J Immunol,2005,175(11):7288-7296.
[6] Dillin A. The specifics of small interfering RNA specificity. PNAS, 2003,100(11):6289-6291;
[7] Sledz CA and Williams BRG. RNA interference in biology and disease. Blood. 2005;106(3):787-794.
[8] Culien B R.Does RNA interference have a future as a treatment for HIV-l induced diseasel.AIDS Rev,2O05,7(1):22-25.
[9] Mccafikey A P,Nakai H,Pandey et a1.Inhibition hepatitis B virus in mice by RNA interference.Nat Biotechnol,20O3,21(6):639-644.
[1] Kim J,Choi WS,Ls S,et al. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells.Blood. 2005,105(5):2206-2213.
[2] Kocak E, Lute K, Chang X, et al.Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity. Cancer Research,2006,66: 7276-7284.
[3] Wehler T C, Nonn M, Brandt B,et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood, 2007, 109(1):365-373.
[4] Fire A, Xu S, Montgomery MK. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature,1998; 391(6669): 806-811.
[5] Geanacopoulos M. An introduction to RNA-mediated gene silencing. Sci Prog. 2005;88(Pt1): 49-69.
[6] Elbashir SM, Harborth J, Weber K, et al. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 2002; 26(2): 199-213.
[7] Lovett-Racke AE, Cravens PD, Gocke AR, et al. Therapeutic potential of small interfering RNA for central nervous system diseases. Arch Neurol. 2005; 62(12):1810-1813.
[8] Meins F, Si-Ammour A, Blevins T. RNA silencing systems and their relevance to plant development. Annu Rev Cell Dev Biol,2005; 21: 297-318.
[9] Brummelkamp TR, Bernards R, Agami R, et al. A system for stable expression of short interfering RNAs in mammalian cells. Science,2002; 296(5567): 550-553.
[10] Gong Y, Jennifer AT, Bingliang F, et al. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer.Oncogene, 2003; 22(36): 5694–5701.
[11] Hu WY,Bushman FD,Siva. RNA interference against retroviruses. VirusRes,2004;102(1):59-64.
[12] Christensen HS,Daher A,Soye KJ,Frankel,et al.Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production.J Virol. 2007;81(10):5121-5131.
[13] Kim J,Choi SP,La S,et al.Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses.Exp Mol Med. 2003;35(6):509-517.
[14] Al-Shamkhani A.CD137: costimulator turns suppressor?Immunology. 2004 ,113(1):23-25.
[15] Sun Y,Chen JH,Fu Y.Immunotherapy with agonistic anti-CD137: two sides of a coin.Cell Mol Immunol. 2004 ;1(1):31-36.
[16] Nam KO,Kang WJ,Kwon BS,et al. The therapeutic potential of 4-1BB (CD137) in cancer.Curr Cancer Drug Targets. 2005;5(5):357-363.
[17] Miyagishi M,Taira K.U6 promoter-driven siRNAs with four uridine 3’- verhangs efficiently suppress targeted gene expression in mammalian cells . Nat Biotechnol.2002,20(5):497-500.
[18] Ohmori T,Kashiwakura Y,Ishiwata A,et al. Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence.Arterioscler Thromb Vasc Biol. 2007,27(10):2266 -2272.
[19] Wakiyama M,Matsumoto T,Yokoyama. Drosophila U6 promoter-driven short hairpin RNAs effectively induce RNA interference in Schneider 2 cells.Biochem Biophys Res Commun. 2005 Jun 17;331(4):1163-1170.
[20] Boden D,Pusch O, Lee F,et al.Promoter choice affects the potency of HIV-1 specific RNA interference.Nucleic Acida Res,2003,3l(17):5033-5038.
[21] Eefting D,Grimbergen JM,de Vries MR,et al.Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA.Hum Gene Ther. 2007;18(9):861-869.
[22] McManus MT, Haines BB, Dillon CP, et al.Small Interfering RNA-Mediated GeneSilencing in T Lymphocytes. The Journal of Immunology, 2002, 169: 5754–5760.
[23] Lofblom J,Kronqvist N,Uhlen M,et al.Optimization of electroporation-mediated transformation: Staphylococcus carnosus as model organism.J Appl Microbiol. 2007;102(3):736-747.
[24] Bassett CL,Janisiewicz WJ. Electroporation and stable maintenance of plasmid DNAs in a biocontrol strain of Pseudomonas syringae.Biotechnol Lett. 2003;25(3):199-203.
[25] Tryfona T,Bustard MT. Enhancement of biomolecule transport by electroporation: a review of theory and practical application to transformation of Corynebacterium glutamicum.Biotechnol Bioeng. 2006;93(3):413-423.
[1] Scherr M,Morgan MA and Eder M.Gene Silencing mediated by small interfering RNAs in mammalian cells.Curr Med Chem,2003,10(3):245-256.
[2] Ginn SL,Fleming J,Rowe PB,et al.Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner.Hum Gene Ther. 2003;14(12):1127-1137.
[3] Logan AC,Haas DL,Kafri T,et al.Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration.J Virol. 2004;78(16):8421-8436.
[4] Sachdeva G,Dcosta J,Cho JE,et al.Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.J Med Virol. 2007;79(2):118-126.
[5] Semple-Rowland SL,Eccles KS and Humberstone EJ.Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters.Mol Vis. 2007;13:2001-2011.
[6] Philippe S,Sarkis C,Barkats M,et al.Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo.Proc Natl Acad Sci U S A. 2006;103(47):17684-17689.
[7] Bao L,Jaligam V,Zhang XY,et al. Stable transgene expression in tumors and metastases after transduction with lentiviral vectors based on human immunodeficiency virus type 1.Hum Gene Ther. 2004;15(5):445-456.
[8] Brummelkamp TR,Bemards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science ,2002,296:550～553.
[9] Amarzguioui M,Rossi JJ and Kim D.Approaches for chemically synthesized siRNA and vector-mediated RNAi.FEBS Lett. 2005;579(26):5974-5981.
[10] Hua J,Mutch DG and Herzog TJ.Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cellline.Gynecol Oncol. 2005;98(1):31-38.
[11] Aigner A.Nonviral in vivo delivery of therapeutic small interfering RNAs.Curr Opin Mol Ther. 2007;9(4):345-352.
[12] Kasahara H and Aoki H. Gene silencing using adenoviral RNAi vector in vascular smooth muscle cells and cardiomyocytes.Methods Mol Med. 2005;112:155-72.
[13] Storvold GL,Gjernes E,Askautrud HA,et al.A retroviral vector for siRNA expression in mammalian cells.Mol Biotechnol. 2007;35(3):275-282.
[14] Matta H,Hozayev B,Tomar R,et al.Use of lentiviral vectors for delivery of small interfering RNA.Cancer Biol Ther. 2003;2(2):206-210.
[15] Gropp M and Reubinoff BE. Lentiviral-RNA-interference system mediating homogenous and monitored level of gene silencing in human embryonic stem cells.Cloning Stem Cells. 2007;9(3):339-45.
[16] Liu YP,Haasnoot J and Berkhout B.Design of extended short hairpin RNAs for HIV-1 inhibition.Nucleic Acids Res. 2007;35(17):5683-5693.
[17] Kim YJ,Ahn J,Jeung SY,et al. Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model.Virus Genes. 2008;36(1):141-146.
[18] Lee SW,Park Y,Song A,et al.Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.J Immunol. 2006;177(7):4464-4472.
[19] Wehler TC,Nonn M,Brandt B,et al.Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.Blood. 2007;109(1):365-373.
[20] Zhang H,Snyder KM,Suhoski MM,et al.4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.J Immunol. 2007;179(7):4910-4918.
[21] Waller EC,Mckinney N,Hicks R,et al. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells.Blood. 2007;110(13):4360-4366.
[22] Sarai M,Hartung D,Petrov A,et al. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging.J Am Coll Cardiol. 2007;50(24):2305-2312.
[23] Wiegard C,Wolint P,Frenzel C,et al. Defective T helper response of hepatocyte-stimulated CD4 T cells impairs antiviral CD8 response and viral clearance.Gastroenterology. 2007;133(6):2010-2018.
[1] Kashfi A, Mehrabi A, Pahlavan PS,et al.A review of various techniques of orthotopic liver transplantation in the rat[J].Transplant Proc, 2005; 37(1): 185-188.
[2] Kamada N,Calne RY.A surgical experience with five hundred thirty liver transplantation in the rat[J].Surgery,1983, 93(1 Pt 1): 64-69.
[3]秦磊,高广勇,余斌,等.改良二袖套法大鼠原位肝脏移植150例报告[J].苏州大学学报(医学版),2005,25(1):77-80.
[4]马毅,何晓顺,陈规划.大鼠原位肝移植模型的手术技巧及并发症的预防[J].中华显微外科杂志,2003,26(1):45-47.
[5]李军,窦科峰,赵青川,等.两套袖法大鼠原位肝移植模型的建立及改进[J].第四军医大学学报,2006,27(9):835-837.
[6] Holzen JP, Palmes D, Langer M,et al.Microsurgical training curriculum for learning kidney and liver transplantation in the rat[J]. Microsurgery,2005, 25(8): 614-623.
[7]刘金彪,郑树国,张玉君,等.提高大鼠原位肝移植手术质量的技巧和注意事项[J].中华器官移植杂志,2005, 26 (8):500-502.
[1] Cho HR,Kwon B,Yagita H,et al.Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.Transpl Int,2004;17(7):351-361.
[2] Detry O,De Roover A,Coimbra C,et al. Recent advances in liver surgery and transplantation. Rev Med Liege. 2007;62(5-6):310-316.
[3] Sugawara Y and Makuuchi M.Liver transplantation for hepatitis B-related cirrhosis: recent advances.J Hepatobiliary Pancreat Surg. 2006;13(5):378-381.
[4] Reding R. Contribution to the study of mechanisms of rejection and tolerance in organ transplantation: minimizing immunosuppression as a strategy for graft tolerance in pediatric liver transplantation.Bull Mem Acad R Med Belg. 2005;160(5-6):265-269.
[5] Perrella O,Sbreglia C,Arenga G,et al. Acute rejection after liver transplantation: Is there a specific immunological pattern?Transplant Proc. 2006;38(10):3594-3596.
[6] Yilmaz F,Aydin U,Nart D,et al. The incidence and management of acute and chronic rejection after living donor liver transplantation.Transplant Proc. 2006;38(5):1435-1437.
[7] Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation, 2004, 77(12): 1815-1820.
[8] Gibelli NE, Pinho-Apezzato ML, et al. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: comparative study. Transplant Proc, 2004, 36(4): 956-957
[9] Suciu-Foca N, Cortesini R. Reviewing the mechanism of peripheral tolerance in clinical transplantation. Contrib Nephrol, 2005, 146(1): 132-142.
[10] Neujahr D, Turka LA. Lymphocyte depletion as a barrier to immunological tolerance[J]. Contrib Nephrol, 2005, 146(1): 65-72.
[11] Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest, 2004, 114(10): 1398-1403.
[12] Kvist M,Lemplesis V,Kanje M,et al. Immunomodulation by costimulation blockade inhibits rejection of nerve allografts.J Peripher Nerv Syst. 2007;12(2):83-90.
[13] Malm H,Pahlman C,Veress B,et al. Combined costimulation blockade prevents rejection of allogeneic islets in mice.Scand J Immunol. 2006;64(4):398-403.
[14] Hosiawa KA,Wang H,DeVries ME,et al. CD80/CD86 costimulation regulates acute vascular rejection.J Immunol. 2005;175(9):6197-6204.
[15] Guillonneau C,Seveno C,Dugast AS,et al. Anti-CD28 antibodies modify regulatorymechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients.J Immunol. 2007;179(12):8164-8171.
[16] Haspot F,Seveno C,Dugast AS,et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells.Am J Transplant. 2005;5(10):2339-2348.
[17] Fan K,Wang H,Wei H,et al. Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance. Transplantation. 2007;84(6):746-754.
[18] McNamara JO,Kolonias D,Pastor F,et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.J Clin Invest. 2008;118(1):376-386.
[19] Elpek KG,Yolcu ES,Franke DD,et al. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.J Immunol. 2007;179(11):7295-7304.
[20] Kroczek R and Hamelmann E. T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies.J Allergy Clin Immunol. 2005;116(4):906-909.
[21] Cao H,Liu H and Wu ZY.Effects of combined immune therapy on survival and Th1/Th2 cytokine balance in rat orthotopic liver transplantation.Chin Med J (Engl). 2007;120(20):1809-1812
[22] Wehler TC,Nonn M,Brandt B,et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood,2007;109(1):365-373.
[23] Rautajoki K,Nyman TA,Lahesmaa R. Proteome characterization of human T helper 1 and 2 cells.Proteomics,2004,4(1):84-92.
[24] Hase T,Chargui J,Inori F,et a1.Human interleukin-10 transduced fetal liver stem cells prolong survival of mouse skin and heart allografts.Transplant Proc,2005,37(1):287-288.
[1] Welch CS. A note on transplantation of the whole liver in dogs.Transplant Bull,1955.2:54.
[2] Cnon JA.Brief report.Transplant Bull,1956.3:7.
[3] Moore FD, Smith LL. Burnap TK, et a1. One-stage homotransplantation of the liver following total hepatectomy in dogs.Transplant Bull,1959, 6(1):103-11O.
[4] Starzl TE,Marchioro TL,VonKaulla KN。et a1. Homotransplantation of the liver in humans.Surg Gynecol Obstet,1963,117:659-676.
[5] Peter S,Heeger.T-Cell alloreeognition transplant rejection:a summary and update.Am J Transplant,2003,3(5):525-533.
[6] Peggs KS,Allison JP.Co-stimulatory pathways in lymphocyte regulation:the imrnuno--globulin superfamily.Br j Haematol,2005,130(6):809-824.
[7] Cho HR,Kwon B,Yagita H,et al.Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.Transpl Int,2004;17(7):351- 361.
[8] Rautajoki K,Nyman TA,Lahesmaa R. Proteome characterization of human T helper 1 and 2 cells.Proteomics,2004,4(1):84-92.
[9] Hase T,Chargui J,Inori F,et a1.Human interleukin-10 transduced fetal liver stem cells prolong survival of mouse skin and heart allografts.Transplant Proc,2005,37(1):287-288.
[10] Aharoni R,Teitelbaum D,Arnon R,et a1.Copolymer 1 inhibits manifestations of graft rejection. Transplantation,2001,72(2):598-605.
[11] Bittmann I,Muller C,Behr J,et a1.Fas/FasL and perforin/granzyme pathway in acute rejection and diffuse alveolar damage after allogeneic lung transplantation - a human biopsy study.Virchows Arch,2004,445(4):375-381.
[12] Ji J,Yu YY,Chen H,et a1.Perforin and granzyme B expression in liver allograft rejection. Zhonghua Gan zang Bing Za Zhi,2004,12(6):325-327.
[13] Thomson Aw ,OConnell PJ,Steptoe RJ,et a1.Immunobiology of liver dendritic cells.Immunol Cell Biol,2002,80(1):65-73.
[14] Weiler-Normann C , Rehermann B.The liver as an Immunological organ . J Gastroenterol Hepatol,2004,19(7):279-283.
[15] Haase C,M Ichdsen BK,Jorgensen TN.CD40 is necessary for activation of naive T cells by a dendritic cell line in vivo but not in vitro.Scand J Immunol,2004,59(3):237-245.
[16] Rentsch M,Puellmann K,Sirek S,et a1.Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat:effects on postischemic reperfusion injury , apoptotic cell death graft regeneration and surviva1.Transpl Int,2005,18(9):1079-1089.
[17] Bertolino P,McCaughan GW,Bowen DG.Role of primary intrahepatic T-cell activation in the liver tolerance effect.Immunol Cell Biol,2002,80(1):84-92.
[18] Fukushi J,Ono M,Morikawa W,et a1.The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13.Immunol,2000,165(5):2818-2823.
[19] Barnes EJ,Abdel-Rehim MM,Goulis Y,et a1.Applications and limitations of blood eosinophilia for the diagnosis of acute cellular rejection in liver transplantation. Am J Transplant,2003,3(4):432-438.
[20] Bishop GA,Sun J,Sheil AG,et a1.High-dose/activation-associated tolerance:a mechanism for allograft tolerance.Transplantation,1997,64:l377-l382.
[21] Yang ZF Ho DW,Chu AC,et a1.Linking inflammation to acut rejection in smal1-for-size liver allografts:the potential role of early macrophage activation.Am J Transplant,2004,4(2):196-209.
[22] Kasahara M,Uryuhara K,Kaihara S,et a1.Monosegmental living donor liver transplantation.Transplant Proc,2003,35(4):1425-1426.
[23] Kasahara M,Kaihara S,Oike F,et a1.Living-donor liver transplantation with monosegments.Transplantation,2003,76(4):694-696.
[24] Sacher T,Knolle P,Nichterlein T,et a1.CpG-ODN-induced inflammarion is suficient to cause T-cell-mediated autoaggression against hepatocytes.Eur J Immunol,2002,32(12):3628-3637.
[25] Kreisel D,Krupnick AS,Gelman AE,et a1.Non-hematopoietic allograft cells directly activate CD8+T cells and trigger acute rejection:all alterative mechanism of allorecognition.Nat Med.2002,8(3):233-239.
[26] Martelius T,Salaspuro V,Salmi M,et a1.Blockade of vascular adhesion protein-l inhibits lymphocyte infiltration in rat liver allograft rejection.Am J Pathol,2004,l65(6):l993-2001.
[27] Crispe IN.Hepatic T cells and liver tolerance.Nat Rev Immunol,2003,3(1):5l-62.
[28] Tesar BM,Zhang J,Li Q,et a1.Thl immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88,a toll-like receptor signal adaptor protein.Am J Transplant,2004,4(9):l429-1439.
[29] Apte UM,McRee R , Ramaiah SK . Hepatocyte proliferation is the possible mechanism for the transient decrease in liver injury during steatosis stage of alcoholic liver disease.Toxicol Pathol,2004,32(5):567-576.
[30] Matzinger P.Friendly and dangerous signals:is the tissue in control? Nat Immunol,2007,8(1):11-13.
[31] Fabrega E,Castro B,Crespo J,et a1.Different time course of circulating adhension molecules and hyaluran during hepatic allograft rejection. Transplantation,2000,69(4):569-573.
[32] Ala A,Dhillon AP,Hodgson HJ.Role of cell adhesion molecules in leukocyte recruitment in the liver and gut.Int J Exp Pathol,2003,84(1):1-56.
[33] Hussain AM,Zhang QX,Murray AG.Endothelial cell calpain activity facilitates lymphocyte diapedesis.Am J Transplant,2005,5(11):2640-2648.
[34] Limmer A , Knolle PA.Liver sinusoidal endothelial cells : a new type of organ-resident antigen-presenting cel1. Arch Immunol Ther Exp(Warsz),2001,49(1):7-11.
[35] Winn RK,Harlan JM.The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost,2005,3(2):1815-1824.
[36] Nakanuma Y,Tsuneyama K,Harada K.Pathology and pathogenesis of intrahepaticbile duct loss.J Hepatobiliary Pancreat Surg,2001,8(4):303-315.
[37] Taylor AL,Gibbs P,Bradley JA.Acute Graft versus host disease following liver transplantation:the enemy within.Am J Transpl,2004,4(4):466-474.
[38] Taylor AL,Sudhindran S,Key T ,et a1. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft versus-host- disease after liver transplantation.Transplantation,2004,77(3):441-446.
[39] Mandelbrot DA ,Sayegh MH.Role of novel T-cell costimulatory pathways in transplantation. Curr Opin Organ Transplantation,2003,8:25-33.
[40] Sudhindran S, Taylor A , Delrivierea L,et a1.Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection.Am J Transpl,2003,3(8):1024-1029.
[41] Huang YM ,Cramer DE ,Ray MB,et a1.The role ofαβ-T andγδ-T cells in allogeneic donor marrow on engraftment , chimerism , and graft-versus-host disease.TranspIantation,2001,72(12):1907-1914.
[42] COSIMI AB , SACHS DH . Mixed chimerism and transplantation tolerance.Transplantation,2004,77(6):943-946.
[43] TRIULZI DJ, NALESNIK MA. Microchimerism ,GVHD,and tolerance in solid organ transplantation.Transfusion,2001,41(3):419-424.
[44] MoNACO AP , MoRRIS PJ . Clinical tolerance : the end of the beginning.Transplantation,2004,77(6):921-925.
[45] SCHLITT HJ,RADDATZ G,STElNHOFF G,et a1.Passenger lymphocytes in human liver allografts and their potential role after transplantation.Transplantation,1993,56(4):95l-955.
[46] POLLACK MS,SPEEG KV,CAllANDER NS,et a1.Severe,late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis.Human Immunology,2005,66(1):28-31.
[47] Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids(3 day taper).Liver Transplant,200l,7(4):343-351.
[48] Barshes NR Goodpastor SE,Goss JA.Pharmacologic immunosuppression. Front Biosci,2004,9:4ll-42O.
[49] Moser MA.Options for induction immunosuppression in liver transplant recipients. Drugs,2002;62(7):995-1011.
[50] Vincenti F,Larsen C,Durrbach A.Costimulation blockade with belatacept in renal transplantation. N Engl Med,2005,353(8):770-781.
[51] changelian PS,Flanagan ME,Ball DJ,et al.Science,2003.302(5646):875-878.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |